Cubist Pharmaceuticals Names New CEO

From DCAT Value Chain Insights (VCI)

By People On The Move posted 10-21-2014 16:10

Cubist Pharmaceuticals Inc. reports that its board of directors has selected Robert J. Perez as the company’s chief executive officer (CEO), effective January 1, 2015. Perez, who currently serves as Cubist’s president and chief operating officer, will succeed Michael W. Bonney, who is retiring from his current role as CEO on December 31, 2014, and will become non-executive chair of Cubist’s board of Directors. Current Board Chair, Kenneth M. Bate, will become lead independent director.
Perez has served in various senior positions at Cubist for 11 years.  He was appointed COO in 2007, president in 2012, and has been a member of the board since April 2014.

Prior to joining Cubist, Perez served as vice president of Biogen Inc.'s CNS Business Unit, where he was responsible for leading the US neurology franchise. From 1995 to 2001, he served as a regional director, director of sales, and Avonex commercial executive at Biogen. From 1987 to 1995, Perez held various sales and marketing positions at Zeneca Pharmaceuticals. 

He is a director at AMAG Pharmaceuticals, Inc. and from 2006 to 2009, he served as a director at EPIX Pharmaceuticals, Inc. He is also a trustee of the Dana-Farber Cancer Institute and a director of the California Healthcare Institute, the Biomedical Science Careers Program, and a member of the Board of Advisors of Citizen Schools of Massachusetts.

Source: Cubist Pharmaceuticals


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription